These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712 [TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis. Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977 [TBL] [Abstract][Full Text] [Related]
6. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. Antonarakis ES; Gomella LG; Petrylak DP Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685 [TBL] [Abstract][Full Text] [Related]
7. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899 [TBL] [Abstract][Full Text] [Related]
8. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144 [TBL] [Abstract][Full Text] [Related]
9. Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. Hatano K; Nonomura N World J Mens Health; 2023 Oct; 41(4):769-784. PubMed ID: 36792090 [TBL] [Abstract][Full Text] [Related]
10. PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects. Parghane RV; Basu S Expert Rev Anticancer Ther; 2023; 23(9):959-975. PubMed ID: 37565281 [TBL] [Abstract][Full Text] [Related]
11. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221 [TBL] [Abstract][Full Text] [Related]
12. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence. Curr Oncol; ; . PubMed ID: 38132385 [TBL] [Abstract][Full Text] [Related]